LONDON–(BUSINESS WIRE)–#Biotechnology–The global epidermolysis bullosa therapeutics market is poised to grow by USD 304.67 million during 2019-2023, progressing at a CAGR of nearly 5% during the forecast period. Request Free Sample Pages
Read the 134-page research report with TOC on “Epidermolysis Bullosa Therapeutics Market Analysis Report by Product (Antibiotics, Analgesics, and Other therapeutics), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 – 2023”.
The rising funds for research on epidermolysis bullosa and growing focus on strengthening of pipeline are factors anticipated to boost the growth of the market.
The current range of therapeutics for the treatment of epidermolysis bullosa available in the market have some side effects. This is prompting various governments and private organizations to release funds to advance the research on the development of promising therapeutics that can eliminate the side effects and offer improved safety and efficacy. For instance, EB Research Partnership is raising funds through partnerships with non-profit organizations, research communities, individual donors, and foundations in the US. Similarly, the Epidermolysis Bullosa Medical Research Foundation (EBMRF) is also funding innovative research to develop a cure for epidermolysis bullosa. The increase in the development of novel therapeutics through such funding and financial support is expected to drive market growth during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Major Five Epidermolysis Bullosa Therapeutics Market Companies:
Amryt Pharma is headquartered in the UK and operates the business under various segments such as Commercial and Research and development. The company offers AP101 (Oleogel-S10), which is a topical drug, to be applied on the skin.
Fresenius is headquartered in Germany and offers products through the following business units: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The company offers ASTRAMORPH PF and Paracetamol Kabi.
Johnson & Johnson
Johnson & Johnson is headquartered in the US and operates under various business segments, namely Consumer, Pharmaceutical, and Medical devices. The company offers MOTRIN and TYLENOL.
Novartis is headquartered in Switzerland and offers products through the following business segments: Innovative medicines, Sandoz, and Alcon. The company offers Gentamicin sulfate and Gabapentin.
Pfizer is headquartered in the US and offers products through the following business segments: Innovative health and Essential health. The company offers BACITRACIN, CORTISPORIN, and LYRICA.
Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform
Epidermolysis Bullosa Therapeutics Product Outlook (Revenue, USD Million, 2019 – 2023)
- Other therapeutics
Epidermolysis Bullosa Therapeutics Regional Outlook (Revenue, USD Million, 2019 – 2023)
- North America
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.